why choose us

First received: September 22, 2023

Clinical Trial: Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Brain Cancer

Study Type: INTERVENTIONAL


Official Title: Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)

Brief Summary: The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

Read more